INTRODUCTION
Coronavirus is a respiratory disease that is spreading worldwide. The
severity and risk of death are important in the elderly, those with
comorbidities, and immunosuppressed patients. The outbreak of a pandemic
has created significant barriers to the diagnosis, treatment, and
monitoring of chronic disease. The provision of regular, planned
comprehensive care for chronic patients has been disrupted due to
medical facility closures, lack of public transportation, or reduced
services. This allowed us to identify rare conditions that would not
normally appear 1,2. Graves’ disease is the most
common cause of hyperthyroidism in iodine-deficient areas, with an
incidence of 21 cases per 100,000 people per year 3.
In addition to the signs and symptoms of hyperthyroidism, Graves’
disease can also include Graves’ o orbitopathy disease (GO), thyroid
dermatopathy (or pretibial myxoma) (PTM), and thyroid
acromopathy5. Rarely, people with Graves’ disease
develop Graves’ dermopathy. This is a condition of the skin that is
characterized by red, swollen skin, usually on the shins and tips of the
feet. There are similarities between the histological features and
pathogenesis of GO and PTM 5. In both cases,
glycosaminoglycan and mucin substances accumulate5. In
both cases, fibroblast proliferation is observed. However, in
dermatopathy, lymphocyte proliferation is less pronounced. The onset of
thyroid dermatopathy occurs on average 12-24 months after diagnosis of
thyrotoxicosis following GO, but in some cases, it can occur many years
after diagnosis of hyperthyroidism6.